Automating the Point of Care: The Getein 1600 and the Push for High-Throughput Decentralized Diagnostics

Getein 1600 Immunofluorescence Quantitative Analyzer | Fully Automated POCT Analyzer for High-Throughput Clinical Diagnostics

The distinction between central lab analyzers and point-of-care testing (POCT) devices is blurring. The Getein 1600 is a fully automated immunofluorescence analyzer that brings central-lab throughput—up to 150 tests per hour—into a compact, POCT form factor. It handles 48 samples with random-access capability, meaning urgent specimens can be inserted without batching delays.

This is not a simple reader. The system automates sampling, dilution, and analysis, reducing hands-on time and the risk of manual error. It accepts whole blood, serum, plasma, and urine with a minimum sample volume of 10 µL. Detection takes under 30 seconds per sample, with full results in 3–15 minutes.

For an ICU or emergency department, that turnaround is critical. For a hospital lab facing rising test volumes, the 150-tests-per-hour throughput shifts the bottleneck away from the instrument and onto pre-analytical workflow. Integration with LIS/HIS systems means results flow directly into patient records without manual entry.

What makes the Getein 1600 noteworthy is not just its specs but what they imply about China’s diagnostic supply chain. The device consolidates multiple assay types—cardiac markers, inflammation, infectious disease—onto a single automated platform, reducing the need for separate instruments. That simplifies procurement for labs and cuts per-test overhead.

From a manufacturing perspective, the system reflects a maturing ecosystem. Chinese POCT manufacturers are no longer producing simple lateral-flow readers; they are engineering integrated platforms with Android-based interfaces, Ethernet connectivity, and internal storage for over 500,000 results. The Getein 1600 competes directly with imported analyzers on throughput and automation.

The real insight is about workflow architecture. As diagnostic demand continues to compress decision-making time, the value is no longer just in the assay itself—it is in how fast the result is actionable.

Why it matters:
For hospital administrators and lab managers, the Getein 1600 represents a path to consolidate testing onto fewer, faster machines. For procurement teams, it signals that Chinese-manufactured POCT platforms can now match the throughput and automation of traditional bench-top analyzers at a potentially lower total cost.

View Product →